A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 18, 2025

Primary Completion Date

September 18, 2026

Study Completion Date

December 16, 2026

Conditions

Health Adult Subjects

Interventions

BIOLOGICAL

GR2303 injection

single dose

BIOLOGICAL

Placebo

single dose

BIOLOGICAL

GR2303 injection

multiple dose

BIOLOGICAL

Placebo

multiple dose

Trial Locations (1)

RECRUITING

Beijing Friendship hospital, Capital Medical University, Beijing

All Listed Sponsors

lead

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

INDUSTRY